LeMaitre Vascular, Inc. (LMAT)

LeMaitre Vascular's stock has been impacted by several key events in the past six months. The company reported strong fourth-quarter and full-year 2025 results, exceeding revenue and earnings estimates, which led to a surge in the stock price. Following the strong performance, LeMaitre Vascular issued upbeat guidance for Q1 and full-year 2026. The company raised its quarterly dividend by 25% and a new $100 million share repurchase authorization was approved. Multiple analysts responded to the positive earnings and outlook by increasing their price targets for LMAT. The stock experienced a "golden cross" event, which is often seen as a bullish technical indicator. Despite positive news, some insider selling activity was disclosed.

The provided search results do not explicitly detail demand seasonality for LeMaitre Vascular's products and services. However, the company's focus on treating peripheral vascular disease and providing devices for surgical procedures suggests that demand might be relatively stable, driven by ongoing medical needs rather than strong seasonal fluctuations. The consistent organic revenue growth and the nature of medical device sales typically indicate a less seasonal demand pattern compared to consumer goods.

LeMaitre Vascular, Inc. is an American medical device company specializing in devices, implants, and services for the treatment of peripheral vascular disease (PVD) and other circulatory conditions. Founded in 1983, the company focuses on serving vascular surgeons and other specialties. LeMaitre Vascular operates within the healthcare sector, specifically in the medical device industry. The company's extensive product portfolio is primarily used in open vascular surgery and dialysis access. Key product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. LeMaitre Vascular also provides human vascular and cardiac tissue cryopreservation services through its RestoreFlow allograft business. Biologic products constituted approximately 53% of the company's sales in 2025.

LeMaitre Vascular has a global presence, selling directly to hospitals in 25 countries and through distributors in over 70 countries across North America, Europe, and Asia/Pacific Rim. The company maintains headquarters in Burlington, Massachusetts, USA, with additional operations and facilities in Sulzbach, Germany, Phoenix, Arizona, St. Petersburg, Florida, Brymbo, Wales, and Tokyo, Japan. In 2025, roughly 95% of net sales originated from territories served by its 160-person direct sales force. The United States accounts for the majority of its revenue.

LeMaitre Vascular generally maintains a positive reputation within its niche market, driven by its focus on specialized, high-margin open-surgery products and a direct-to-hospital sales model. The company's consistent organic revenue growth and profitability contribute to a strong market position. However, LeMaitre Vascular disclosed an FDA warning letter at its North Brunswick facility. In January 2026, the company experienced a cybersecurity incident that affected certain systems and data.

LeMaitre Vascular's ownership structure is primarily composed of institutional investors, who hold a significant majority of the company's shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Conestoga Capital Advisors, LLC, State Street Corp / State Street Global Advisors, Inc., iShares Core S&P Small-Cap ETF (IJR), First Trust Advisors Lp, Copeland Capital Management, LLC, Congress Asset Management Co /ma, T. Rowe Price Group, Inc., Dimensional Fund Advisors, Inc., and Geode Capital Management LLC. Major individual owners (insiders) include George W. LeMaitre (Chairman and CEO), David B. Roberts (President and Director), John James O'Connor (Director), and Joseph P. Pellegrino, Jr. (formerly CFO, now Director).